Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Clinical trial NCT06674343 · RECRUITING
Trial details
- NCT number
- NCT06674343
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-15
- Primary completion
- 2026-12-31
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.